Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have been assigned an average rating of “Moderate Buy” from the nine brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $24.4286.

A number of research firms have recently issued reports on DAWN. Weiss Ratings reissued a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research report on Monday, December 1st. Piper Sandler increased their target price on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, November 24th. JPMorgan Chase & Co. boosted their price target on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $16.00 price objective on shares of Day One Biopharmaceuticals in a report on Monday, November 24th.

Insider Transactions at Day One Biopharmaceuticals

In other news, insider Adam Dubow sold 4,319 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $8.91, for a total transaction of $38,482.29. Following the completion of the sale, the insider directly owned 62,626 shares of the company’s stock, valued at $557,997.66. This trade represents a 6.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jeremy Bender sold 15,894 shares of Day One Biopharmaceuticals stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $8.91, for a total value of $141,615.54. Following the sale, the chief executive officer owned 177,165 shares of the company’s stock, valued at approximately $1,578,540.15. This represents a 8.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 28,001 shares of company stock valued at $249,489. 6.20% of the stock is currently owned by company insiders.

Institutional Trading of Day One Biopharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Federated Hermes Inc. acquired a new position in shares of Day One Biopharmaceuticals during the 3rd quarter worth $39,000. Ameritas Investment Partners Inc. lifted its stake in shares of Day One Biopharmaceuticals by 44.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock valued at $48,000 after purchasing an additional 2,264 shares during the last quarter. Quarry LP bought a new stake in Day One Biopharmaceuticals in the third quarter worth $49,000. Entropy Technologies LP acquired a new position in Day One Biopharmaceuticals during the second quarter worth $67,000. Finally, Prudential Financial Inc. bought a new position in Day One Biopharmaceuticals during the second quarter valued at about $69,000. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Trading Down 5.0%

Shares of DAWN stock opened at $7.92 on Monday. The company has a market capitalization of $813.23 million, a price-to-earnings ratio of -5.21 and a beta of -1.28. Day One Biopharmaceuticals has a 1-year low of $5.64 and a 1-year high of $13.92. The stock’s fifty day simple moving average is $8.10 and its 200-day simple moving average is $7.26.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.09. Day One Biopharmaceuticals had a negative return on equity of 32.05% and a negative net margin of 113.53%.The firm had revenue of $39.80 million during the quarter, compared to analyst estimates of $38.20 million. During the same period last year, the company posted $0.38 EPS. The business’s quarterly revenue was down 57.6% compared to the same quarter last year. On average, sell-side analysts predict that Day One Biopharmaceuticals will post -0.72 EPS for the current year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.